Adding trastuzumab for HER+ status to a ﬁrst-line regimen of emavusertib plus folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and a PD-1 inhibitor (nivolumab or pembrolizumab) for metastatic or unresectable esophageal, GEJ, or gastric cancer has proven encouraging…